Eagle Asset Management Inc. Decreases Holdings in LivaNova PLC (NASDAQ:LIVN)

Eagle Asset Management Inc. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 8.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 140,341 shares of the company’s stock after selling 12,155 shares during the period. Eagle Asset Management Inc. owned about 0.29% of LivaNova worth $11,804,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in LIVN. Point72 Hong Kong Ltd purchased a new stake in LivaNova during the 1st quarter valued at $27,000. IndexIQ Advisors LLC purchased a new stake in LivaNova during the 1st quarter valued at $29,000. Captrust Financial Advisors raised its stake in LivaNova by 1,066.3% during the 1st quarter. Captrust Financial Advisors now owns 1,108 shares of the company’s stock valued at $82,000 after buying an additional 1,013 shares during the last quarter. Meeder Asset Management Inc. raised its stake in LivaNova by 23.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 981 shares of the company’s stock valued at $83,000 after buying an additional 187 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC purchased a new stake in LivaNova during the 1st quarter valued at $163,000. Institutional investors and hedge funds own 94.97% of the company’s stock.

Shares of LivaNova stock opened at $82.04 on Thursday. The company has a market capitalization of $4.02 billion, a P/E ratio of -10.53 and a beta of 0.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.15. The company has a fifty day moving average of $82.48 and a 200 day moving average of $81.50. LivaNova PLC has a fifty-two week low of $41.07 and a fifty-two week high of $90.25.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, July 28th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.19. The company had revenue of $264.50 million during the quarter, compared to the consensus estimate of $241.73 million. LivaNova had a negative net margin of 37.15% and a positive return on equity of 8.44%. Analysts forecast that LivaNova PLC will post 1.57 EPS for the current year.

In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Wednesday, September 1st. The shares were sold at an average price of $82.40, for a total transaction of $82,400.00. Following the completion of the transaction, the director now owns 31,630 shares of the company’s stock, valued at approximately $2,606,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.37% of the stock is owned by corporate insiders.

LIVN has been the subject of several analyst reports. Zacks Investment Research upgraded LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, August 4th. Needham & Company LLC upped their price objective on LivaNova from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, August 20th. Piper Sandler reduced their price objective on LivaNova from $99.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday, June 1st. Finally, Robert W. Baird upped their price objective on LivaNova from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 17th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $101.00.

LivaNova Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.

Featured Article: What is required to own or exchange cryptocurrency?

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.